KCT0003812尚未招募未知
A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of MS on improving liver function
ChongKunDang Healthcare0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 75(Year)（—）
- 性别
- All
入选标准
- •1) Adult male and female between 19-75 years
- •2) ?-GTP = 70 IU/L and = 180 IU/L
- •3) In the alcohol drinking style survey, Subject who drinks more than average 14 unit of male, 7 unit of female per week during the past month.
- •4) Subject who voluntarily agrees to participate and sign in informed consent form
排除标准
- •1) Subject who are admitted to hospital, medication or rehabilitation due to alcohol use disorder ? related disorder, heart disease, central nervous disorder, etc
- •2) Abdominal ultrasound exam showed liver cirrhosis or liver cancer patients
- •3) Subject who more than 3times the upper limit of normal AST(GOT) or ALT(GPT) of clinical trial institution
- •4) Subject who more than 3times the upper limit of normal ALP or Platelet = 105/µL or AFP > 10ng/mL
- •5) Subject who have been diagnosed with viral hepatitis
- •6) Subjcet who were positive HBs Ag or HCV Ab in screening test
- •7) Subject who Albumin = 3g/dl or Total Bilirubin = 3mg/dl
- •8) Subject who more than 1.5times the upper limit of normal Creatinine
- •9) Uncontrolled thyroid disease patient
- •10) Subject who was taking drugs the affects liver function within 4 weeks of study(antituberculosis drugs, anticonvulsants, arthrifuges, antidepressants and other drugs that may cause hepatotoxicity)
- •11) Subject who was taking NSAIDs, antiviral agents, antibiotics within 2 weeks of study
- •12) Subject who was taking cholagogues, Cholelitholytics & Hepatic Protectors, antidotes, Detoxifying Agents & Drugs Used in Substance Dependence within 4 weeks of study
- •13) Subject who was taking herbal medicine, Vitamine.E supplements, and health functional foods related to liver function improvement within 2 weeks of study
- •14) Subject who was taking corticosteroids or sex hormones within 4 weeks of study
- •15) Patients with uncontrolled hypertension(systolic BP = 160 mmHg or diastolic BP = 100 mmHg, measurement after stabilization for 10 minutes of test subjects
- •16) Uncontrolled diabetic(fasting blood glucose = 180mg/dl or If the drug is newly started or changed due to diabetes within 3 months or in case of using of insulin)
- •17) Subject who have dosed Anti-phospholipid drugs within 3 months (They can participate if they have been on treatment since 3 months)
- •18) Subject who have severe gastrointestinal symptoms such as heartburn, indigestion, etc.
- •19) Subject who is pregnant or has a pregnancy plan during the period of the clinical trial
- •20) Subject who has planned to participate in other clinical trials during the clinical trial study
- •21) Subject who have participated other clinical trials within the past month
- •22) Subject who the opinion investigator make a judgment to be unsuitable
研究者
相似试验
尚未招募
不适用
A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of HT083 on mild OsteoarthritisKCT0004925The Catholic University of Korea, Uijeongbu St. Mary’s Hospital100
招募中
不适用
A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of KBL693 on atopic dermatitis in childreDiseases of the skin and subcutaneous tissueKCT0005895Kobiolabs159
招募中
不适用
Clinical trial for the evaluation of the efficacy and safety of NIHHS-18-42458 on improving liver functioDiseases of the digestive systemKCT0004392ational Institute of Horticultural and Herbal Science90
已完成
不适用
Clinical trial for the evaluation of the efficacy and safety of KACC91563 on atopic dermatitis in childreKCT0003822Aram100
招募中
不适用
A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of TabetriTM on atopic dermatitis in childreDiseases of the skin and subcutaneous tissueKCT0002640utri Biotech60